These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 24684351)

  • 21. The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected].
    Filippatos TD; Athyros VG; Elisaf MS
    Expert Opin Drug Metab Toxicol; 2014 Jun; 10(6):787-812. PubMed ID: 24746233
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes.
    Covington P; Christopher R; Davenport M; Fleck P; Mekki QA; Wann ER; Karim A
    Clin Ther; 2008 Mar; 30(3):499-512. PubMed ID: 18405788
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Saxagliptin (Onglyza) for type 2 diabetes.
    Med Lett Drugs Ther; 2009 Nov; 51(1324):85-6. PubMed ID: 19890244
    [No Abstract]   [Full Text] [Related]  

  • 24. Demographic and Clinical Characteristics of Patients With Type 2 Diabetes Mellitus Initiating Dipeptidyl Peptidase 4 Inhibitors: A Retrospective Study of UK General Practice.
    Tebboth A; Lee S; Scowcroft A; Bingham-Gardiner P; Spencer W; Bolodeoku J; Hassan SW
    Clin Ther; 2016 Aug; 38(8):1825-1832.e15. PubMed ID: 27491279
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Saxagliptin: a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus.
    Neumiller JJ; Campbell RK
    Am J Health Syst Pharm; 2010 Sep; 67(18):1515-25. PubMed ID: 20811029
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiovascular Safety of Incretin-Based Therapies in Type 2 Diabetes: Systematic Review of Integrated Analyses and Randomized Controlled Trials.
    Mannucci E; Monami M
    Adv Ther; 2017 Jan; 34(1):1-40. PubMed ID: 27844335
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is the Use of DPP-4 Inhibitors Associated With an Increased Risk for Heart Failure? Lessons From EXAMINE, SAVOR-TIMI 53, and TECOS.
    Schernthaner G; Cahn A; Raz I
    Diabetes Care; 2016 Aug; 39 Suppl 2():S210-8. PubMed ID: 27440835
    [No Abstract]   [Full Text] [Related]  

  • 28. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes.
    Rosenstock J; Sankoh S; List JF
    Diabetes Obes Metab; 2008 May; 10(5):376-86. PubMed ID: 18355324
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An update on the clinical pharmacology of the dipeptidyl peptidase 4 inhibitor alogliptin used for the treatment of type 2 diabetes mellitus.
    Chen XW; He ZX; Zhou ZW; Yang T; Zhang X; Yang YX; Duan W; Zhou SF
    Clin Exp Pharmacol Physiol; 2015 Dec; 42(12):1225-38. PubMed ID: 26218204
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Alogliptin (Vipidia): a selective DPP-4 inhibitor with a good cardiovascular safety].
    Scheen AJ
    Rev Med Liege; 2014; 69(7-8):460-6. PubMed ID: 25158388
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Saxagliptin plus metformin combination in patients with type 2 diabetes and renal impairment.
    Scheen AJ
    Expert Opin Drug Metab Toxicol; 2012 Mar; 8(3):383-94. PubMed ID: 22313172
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Saxagliptin, alogliptin, and cardiovascular outcomes.
    Standl E
    N Engl J Med; 2014 Jan; 370(5):483. PubMed ID: 24476445
    [No Abstract]   [Full Text] [Related]  

  • 33. Alogliptin: safety, efficacy, and clinical implications.
    Marino AB; Cole SW
    J Pharm Pract; 2015 Feb; 28(1):99-106. PubMed ID: 24532820
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Saxagliptin, a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
    Gallwitz B
    IDrugs; 2008 Dec; 11(12):906-17. PubMed ID: 19051153
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of the Risk of Hospitalization for Heart Failure With Dipeptidyl Peptidase-4 Inhibitors, Saxagliptin, Alogliptin, and Sitagliptin in Patients With Type 2 Diabetes, Using an Alternative Measure to the Hazard Ratio.
    Kaneko M; Narukawa M
    Ann Pharmacother; 2017 Jul; 51(7):570-576. PubMed ID: 28622738
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
    Deacon CF; Holst JJ
    Adv Ther; 2009 May; 26(5):488-99. PubMed ID: 19444391
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alogliptin; a review of a new dipeptidyl peptidase-4 (DPP-4) inhibitor for the treatment of type 2 diabetes mellitus.
    Said S; Nwosu AC; Mukherjee D; Hernandez GT
    Cardiovasc Hematol Disord Drug Targets; 2014; 14(1):64-70. PubMed ID: 24993124
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Saxagliptin: a new dipeptidyl peptidase 4 inhibitor for type 2 diabetes.
    Borja-Hart NL; Whalen KL
    Ann Pharmacother; 2010 Jun; 44(6):1046-53. PubMed ID: 20460554
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study.
    Nowicki M; Rychlik I; Haller H; Warren M; Suchower L; Gause-Nilsson I; Schützer KM
    Int J Clin Pract; 2011 Dec; 65(12):1230-9. PubMed ID: 21977965
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increased risk of bullous pemphigoid in dipeptidyl peptidase 4 inhibitors: A nationwide, population-based, cohort study in Taiwan.
    Hung CT; Liu JS; Cheng CY; Chung CH; Chiang CP; Chien WC; Wang WM
    J Dermatol; 2020 Mar; 47(3):245-250. PubMed ID: 31885117
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.